Evidence map›Paper›PMID 26359487›Full record

SynthesisAnnals of the rheumatic diseases2015

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Tuhina Neogi, Tim L Th A Jansen, Nicola Dalbeth, Jaap Fransen, H Ralph Schumacher, Dianne Berendsen, Melanie Brown, Hyon Choi, N Lawrence Edwards, Hein J E M Janssens and 12 more

Erratum issuedOpen access · hybridAbstract readConsensus StatementSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of the rheumatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 400 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
400citing papers in PubMed, 3 pooled it
34.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

400 citing papers in PubMed, 3 syntheses or guidelines pooled it, 880 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Article
  20. Article

340 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 16 institutions in 9 countries.

Tuhina NeogiBoston University School of Medicine, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0002-9515-1711
Tim L Th A JansenViecuri Medical Center, Venlo, The Netherlands Radboud University Medical Center, Nijmegen, The Netherlands.
Nicola DalbethUniversity of Auckland, Auckland, New Zealand.
Jaap FransenRadboud University Medical Center, Nijmegen, The Netherlands.
H Ralph SchumacherUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dianne BerendsenRadboud University Medical Center, Nijmegen, The Netherlands.
Melanie BrownUniversity of Otago, Wellington, New Zealand.
Hyon ChoiBoston University School of Medicine, Boston, Massachusetts, USA.
N Lawrence EdwardsUniversity of Florida, Gainesville, Florida, USA.
Hein J E M JanssensRadboud University Medical Center, Nijmegen, The Netherlands.
Frédéric LiotéINSERM UMR 1132, Hôpital Lariboisière, AP-HP, and Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Raymond P NadenMcMaster University Medical Centre, Hamilton, Ontario, Canada.
George NukiUniversity of Edinburgh, Edinburgh, UK.
Alexis OgdieUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Fernando Perez-RuizHospital Universitario Cruces and BioCruces Health Research Institute, Vizcaya, Spain.
Kenneth SaagUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Jasvinder A SinghBirmingham VA Medical Center and University of Alabama at Birmingham, and Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
John S SundyDuke University and Duke University Medical Center, Durham, North Carolina, USA Gilead Sciences, Foster City, California, USA.
Anne-Kathrin TauscheUniversity Hospital Carl Gustav Carus, Dresden, Germany.
Janitzia Vaquez-MelladoHospital General de Mexico, Mexico City, Mexico.
Steven A YarowsUniversity of Michigan Health System, Chelsea.
William J TaylorUniversity of Otago, Wellington, New Zealand.
Radboud University Nijmegen · NLBoston University · USUniversity of Otago · NZUniversity of Pennsylvania · USBioCruces Health research Institute · ESDuke University · USHospital General de México · MXInserm · FRMayo Clinic · USMcMaster University Medical Centre · CAUniversity Health System · USUniversity Hospital Carl Gustav Carus · DEUniversity of Alabama at Birmingham · USUniversity of Auckland · NZUniversity of Edinburgh · GBUniversity of Florida · US

Funding

WORK DISABILITY-- PERSONS WITH RHEUMATOID ARTHRITISP60AR047785 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZHANG, YUQING · 2001 to 2016
$18.0M
Predictors and Consequences of Subchondral Bone Attrition in OsteoarthritisK23AR055127 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI NEOGI, TUHINA · 2007 to 2011
$631k
NIAMS NIH HHS K23 AR055127NIAMS NIH HHS P60 AR047785
6 · The paper itself

Abstract

objectiveExisting criteria for the classification of gout have suboptimal sensitivity and/or specificity, and were developed at a time when advanced imaging was not available. The current effort was undertaken to develop new classification criteria for gout.

methodsAn international group of investigators, supported by the American College of Rheumatology and the European League Against Rheumatism, conducted a systematic review of the literature on advanced imaging of gout, a diagnostic study in which the presence of monosodium urate monohydrate (MSU) crystals in synovial fluid or tophus was the gold standard, a ranking exercise of paper patient cases, and a multi-criterion decision analysis exercise. These data formed the basis for developing the classification criteria, which were tested in an independent data set.

resultsThe entry criterion for the new classification criteria requires the occurrence of at least one episode of peripheral joint or bursal swelling, pain, or tenderness. The presence of MSU crystals in a symptomatic joint/bursa (ie, synovial fluid) or in a tophus is a sufficient criterion for classification of the subject as having gout, and does not require further scoring. The domains of the new classification criteria include clinical (pattern of joint/bursa involvement, characteristics and time course of symptomatic episodes), laboratory (serum urate, MSU-negative synovial fluid aspirate), and imaging (double-contour sign on ultrasound or urate on dual-energy CT, radiographic gout-related erosion). The sensitivity and specificity of the criteria are high (92% and 89%, respectively).

conclusionsThe new classification criteria, developed using a data-driven and decision-analytic approach, have excellent performance characteristics and incorporate current state-of-the-art evidence regarding gout.

Indexed as

Decision Support TechniquesDiagnostic ImagingEvidence-Based MedicineGoutHumansInternational CooperationTomography, X-Ray ComputedArthritisGoutSynovial fluid

Identifiers

PMID26359487
PMCPMC4602275
OpenAlexW2217064679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.